InvestorsHub Logo
Followers 59
Posts 18522
Boards Moderated 0
Alias Born 11/29/2006

Re: staccani post# 1153

Friday, 02/10/2017 2:25:18 PM

Friday, February 10, 2017 2:25:18 PM

Post# of 2104
I took those twitter comments to say that ICPT is changing the endpoints. Are they allowed to do that?

This from The Fly (free comments)

08:45 Intercept CEO says OCA phase 3 trial changes make positive results more likely Intercept Pharmaceuticals CEO Mark Pruzanski said the company continues to be confident on both endpoints, but now only needs to hit on either NASH resolution or fibrosis improvement for the trial to be considered a success. Read more at: http://thefly.com/landingPageNews.php?id=2503483

Read more at:
http://thefly.com/landingPageNews.php?id=2503483

Intercept analyst commentary at Leerink Leerink 'not convinced' Intercept trial changes up chance of success. Leerink analyst Joseph Schwartz says he's "not convinced" the endpoint changes raise the probability of success for Intercept Pharmaceuticals' obeticholic acid. It is discouraging that enrolling the 1,400 patient cohort was unattainable in a timely manner, Schwartz tells investors in a research note. Read more at: http://thefly.com/landingPageNews.php?id=2503649

Read more at:
http://thefly.com/landingPageNews.php?id=2503649